Solid Cancer Treatment
Solid Cancer Treatment - Related Videos
05:58
Method for Obtaining Primary Ovarian Cancer Cells From Solid Specimens
0 Views •
Cited by 13 •
2014
This study describes a detailed method for isolation and characterization of primary ovarian cancer cells from solid clinical specimens. Ovarian cancer clinical specimens are subjected to enzymatic digestion to obtain viable, fibroblast-free epithelial ovarian cancer (EOC) cells highly suitable for downstream applications.
08:08
Quantitative Mass Spectrometric Profiling of Cancer-cell Proteomes Derived From Liquid and Solid Tumors
0 Views •
Cited by 7 •
2015
In-depth analyses of cancer cell proteomes facilitate identification of novel drug targets and diagnostic biomarkers. We describe an experimental workflow for quantitative analysis of (phospho-)proteomes in cancer cell subpopulations derived from liquid and solid tumors. This is achieved by combining cellular enrichment strategies with quantitative Super-SILAC-based mass spectrometry.
07:29
Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
0 Views •
Cited by 27 •
2015
Pancreatic cancer stem cells (CSCs) can be expanded in vitro using the anchorage-independent sphere culture technique, which represents a powerful tool to study CSC biology and can serve as the first step to develop novel CSC-targeting therapies. Here the methodology for expanding, analyzing and targeting of pancreatic CSCs is provided.
02:56
Treatment Resistent Cancers
0 Views •
2023
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56
Treatment Resistant Cancers
0 Views •
2021
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
FAQs
These factors determine how extensive the disease is, where treatment can be delivered, and which cancer-cell processes may be vulnerable to therapy. A localized tumor may be approached differently from disease requiring systemic control, while molecular features can support selection of targeted medicines or immunotherapy. Considering these variables helps clinicians tailor treatment rather than applying one regimen to every tumor.
Radiation therapy acts by damaging the DNA of cancer cells. This injury can limit their ability to proliferate, helping control or eliminate tumor tissue. Its role is especially relevant when treatment must be directed toward a defined tumor site. In a broader treatment plan, radiation may be considered alongside surgery or systemic medicines according to tumor characteristics and clinical goals.
Local approaches, such as surgery and radiation, act primarily at a specific tumor site. Systemic medicines, including chemotherapy, targeted therapy, and immunotherapy, are intended to work throughout the body by inhibiting proliferation or engaging the immune system. This distinction helps explain why treatment planning considers both the tumor’s location and whether broader control is needed.
Surgery can remove a localized tumor when its position and extent make physical removal a suitable strategy. Its value lies in directly reducing or eliminating tumor tissue at the affected site, although treatment decisions still depend on tumor type, stage, and location. Surgery may therefore form part of a broader plan that also includes radiation or systemic medicines.
Biomarker testing examines molecular features that can help distinguish which treatments are more appropriate for an individual tumor. These findings may inform the use of targeted therapy or immunotherapy and contribute to personalized clinical decision-making. Because molecular characteristics differ among tumors, testing can refine treatment selection beyond information provided by the tumor’s organ of origin alone.
The intended outcome varies with the cancer and its clinical circumstances. Treatment may cure some cancers, reduce the chance that disease returns, relieve symptoms, or extend survival. These goals influence how clinicians weigh surgery, radiation, and systemic medicines, including whether a combination approach is appropriate. Ongoing improvements in biomarkers and combination regimens continue to shape these decisions.